An observational study in Histiocytosis, sponsored by Memorial Sloan Kettering Cancer Center. Active, not recruiting at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-07.
Sponsored by Memorial Sloan Kettering Cancer Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Histiocytosis with a site in United States — 2 open to participants now, 5 under way, none of them phase 3. Histiocytosis · United States.
Among the 14 studies in Histiocytosis with a site in United States, this one is the only one that started in 2017, is one of 3 observational ones, and was the 12th registered.
25 studies on the registry are indexed under Histiocytosis; 8 are open to participants now.
Browse Histiocytosis studies →2 of the 14 studies in Histiocytosis with a site in United States are open now. Recruiting first, the newest first:
Institut de Recherches Internationales Servier · Sites in United States, Australia, China and 7 more countries
Ages 18+
University of Alabama at Birmingham · Sites in United States
Ages 0–89
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 4 Histiocytosis studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 2 take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8
First in 2000; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 21 across the 10 interventional studies, 463 across the 3 observational. Of the 8 that completed or were terminated, 2 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 14 have an industry lead sponsor. The 10 most frequent:
Memorial Sloan Kettering Cancer Center is the lead sponsor of 1,964 studies on the registry; 325 are open to participants now.
Of its 135 completed or terminated interventional studies of FDA-regulated products, 71 (53%) have results posted.
Memorial Sloan Kettering Cancer Center has 1 study filed under Histiocytosis — fewer than ten, so there is no comparison to draw.
2 of the studies in Histiocytosis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03127709Memorial Sloan Kettering Cancer CenterA Study of Memory, Thinking, and Brain Imaging in Adults With Histiocytosis | 2027-04 |
| NCT05915208University of Alabama at BirminghamHistiocytic Disorder Follow-up Study | 2027-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies in Histiocytosis with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to try to understand how histopcytosis can cause symptoms or problems in the brain. The tests being done in the study will look at memory and thinking as well as brain function via MRI scan.
Participants will have a diagnosis of a histiocytic disorder as determined, in the opinion of the study PI, by a corroborating constellation of histopathology, clinical, and/or radiologic findings.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will have a histiocytic disorder as determined by a corroborating constellation of histopathology, clinical, and/or radiologic findings.
Behavioral: Trail Making Test, Parts A & B · Behavioral: Brief Test of Attention · Behavioral: Symbol Span · Behavioral: Controlled Oral Word Association Test · Behavioral: The Hopkins Verbal Learning Test-Revised · Behavioral: Brief Visuospatial Memory Test-Revised · Behavioral: Hospital Anxiety and Depression Scale · Behavioral: McGill Quality of Life Scale · Diagnostic Test: MR Brain Imaging · Diagnostic Test: Resting state functional MRI · Behavioral: Functional Assessment of Cancer Therapy Cognitive Scale (FACT-Cog)
Part A is a timed measure of visual scanning and graphomotor speed. Part B is a timed measure of cognitive flexibility.
Assesses auditory working memory
Also known as: BTA
Assesses visual working memory
Also known as: WMS-IV
The COWA timed test of phonemic verbal fluency. It requires the subject to generate as many words as possible, beginning with a given letter of the alphabet (i.e., F, A, and S).
Also known as: COWA
HVLT-R is a test of verbal learning and memory. Scores obtained are the total number of words.
Also known as: HVLT-R
The BVMT-R is a test of visuospatial learning and memory.
Also known as: BVMT-R
The HADS is a brief assessment validated in many cancer populations.
Also known as: HADS
This is a questionnaire that is a validated 17-item QOL instrument validated for ill patients and in the particular context of the ancer.
Also known as: McGill QOL
Standard of care brain MR imaging includes high-resolution 3D T1-weighted images in the axial plane. The axial T1-weighted images will be isotropic with a typical matrix size of 256 x 256, 256 mm field-of-view (FOV) and 1 mm slice thickness covering the whole brain.
Scanning will be performed on a 3 Tesla General Electric scanner (Optima 750W) with a GEM HNU 24-channel head coil. rsFMRI matching the FLAIR and T1 post-contrast images will be obtained. For resting state fMRI, T2\*-weighted images will be acquired with a single-shot gradient echo echo-planar imaging (EPI) sequence in the axial orientation (TR = 2500 ms, TE = 30 ms, FA = 80°, slice thickness = 4 mm, FOV= 240mm2, matrix=64×64) covering whole brain. For the resting state fMRI portion of the scan, patients will be instructed by the technologist or research staff to leave eyes open, focus on looking at a crosshair, and not think about anything during the scan.
Also known as: rsFMRI
This is a validated 37-item QOL instrument for cancer patients with cognitive complaints. The measures consist of FACT-Cog total, perceived cognitive impairments, perceived cognitive abilities, and impact on quality of life.
neurocognitive function
Neurocognitive tests will yield raw scores that are converted to z-scores, normalized for participant's age, sex and educational level.The proportion of participants demonstrating cognitive impairment (as defined by 2 or more z-scores less than -1.5) will be summarized. Also, the proportion of participants with impairment (z \< -1.5) for each cognitive test will be summarized. In this way the cognitive assessment yields a dichotomous outcome of impaired versus not impaired for each participant but also allow for more granular assessment of impairment in specific cognitive domains.
Time frame: 1 year
quality of life
questionnaires will yield raw scores (total score for HADS and McGill QOL, as well as anxiety and depression subscores for the HADS). QOL scores will be analyzed as raw scores. Cognitive test scores will be transformed into z-sores (based on score distributions from established normative samples with a mean of 0 and standard deviation of 1) to define the presence/severity of cognitive dysfunction. Scores will be normalized for age, sex and education.
Time frame: 1 year
comparing of grey matter volume
In a whole-brain analysis, first, cortical thickness will be compared between participants and controls and regions of statistically significant grey matter loss will be identified. This is done computionally with a whole-brain, vertex-by-vertex approach, as stated above. Also, as stated above (Section 7), statistical significance thresholding is at p\<0.001, correcting for multiple comparisons using the False Discovery Rate (FDR) method and clustering thresholds, methods used in various high-throughput contexts, including MRI analysis.
Time frame: 1 year
Plan to share: Undecided
Started Apr 2017 (actual). Primary completion is estimated for Apr 2027, 120 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Memorial Sloan Kettering Cancer Center →